Form 8-K - Current report:
SEC Accession No. 0001628280-23-019604
Filing Date
2023-05-24
Accepted
2023-05-24 17:02:30
Documents
13
Period of Report
2023-05-24
Items
Item 4.01: Changes in Registrant's Certifying Accountant

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230524.htm   iXBRL 8-K 38830
2 EX-16.1 a00exhibit161fromforvis.htm EX-16.1 2621
  Complete submission text file 0001628280-23-019604.txt   180471

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230524.xsd EX-101.SCH 2011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230524_lab.xml EX-101.LAB 24152
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230524_pre.xml EX-101.PRE 12609
7 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230524_htm.xml XML 11014
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 23954952
SIC: 2834 Pharmaceutical Preparations